Balyasny Asset Management
CADL icon

Balyasny Asset Management’s Candel Therapeutics CADL Stock Holding History

Balyasny Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Buy
73,495
+30,287
+70% +$229K ﹤0.01% 2352
2026
Q1 		$212K Buy
+43,208
New +$235K ﹤0.01% 2684
2025
Q4 		– Sell
-49,483
Closed -$252K – 3119
2025
Q3 		$252K Buy
+49,483
New +$286K ﹤0.01% 2641
2025
Q2 		– Sell
-37,710
Closed -$213K – 2862
2025
Q1 		$213K Buy
+37,710
New +$308K ﹤0.01% 2567

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management's CADL Position: Q2 2026 in Review

Balyasny Asset Management increased its Candel Therapeutics (CADL) stake by 70% in Q2 2026, buying an estimated $229K and bringing the position to 73,495 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #2352.

Balyasny Asset Management first reported a position in CADL in Q1 2025 and has held it in 4 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Balyasny Asset Management held 73,495 shares of Candel Therapeutics worth $757K as of Q2 2026.
  • Balyasny Asset Management bought 30,287 Candel Therapeutics shares in Q2 2026, an estimated $229K.
  • Candel Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2352 holding.
  • Balyasny Asset Management first reported a position in Candel Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.